Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Total Non-Current Liabilities (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Total Non-Current Liabilities for 16 consecutive years, with $675.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Non-Current Liabilities rose 15.71% year-over-year to $675.6 million, compared with a TTM value of $675.6 million through Dec 2025, up 15.71%, and an annual FY2025 reading of $675.6 million, up 15.71% over the prior year.
  • Total Non-Current Liabilities was $675.6 million for Q4 2025 at Amicus Therapeutics, up from $638.4 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $675.6 million in Q4 2025 and bottomed at $532.8 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $598.1 million, with a median of $602.4 million recorded in 2025.
  • The sharpest move saw Total Non-Current Liabilities surged 72.59% in 2021, then fell 5.46% in 2024.
  • Year by year, Total Non-Current Liabilities stood at $577.4 million in 2021, then grew by 3.3% to $596.5 million in 2022, then grew by 3.55% to $617.6 million in 2023, then decreased by 5.46% to $583.9 million in 2024, then grew by 15.71% to $675.6 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for FOLD at $675.6 million in Q4 2025, $638.4 million in Q3 2025, and $602.4 million in Q2 2025.